Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$7MCash on Hand
8.9mo Cash Runway
Follow CANF by emailGet an email when CANF reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CANF, unsubscribe in one click. Privacy
📣 What CANF Says Is Next
first quarter of 2027 · Piclidenoson: “The Company’s lead drug candidate, Piclidenoson, is being evaluated in a pivotal Phase III study for the treatment of moderate-to-severe plaque psoriasis, which has completed enrollment of the first 247 patients for a pre-specified interim analysis, with interim efficacy and safety data expected in the first quarter of 2027.”
Company press release, Nov 12, 2026 · SEC filing
Q4 2026 · “Results are expected during Q4 2026/Q1 2027.”
Company press release, Jul 6, 2026 · SEC filing
Q4 2026 · “An interim analysis from the Phase III study is expected to be in approximately Q4 2026.”
Company press release, Dec 16, 2025 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 12, 2026 ·
Clinical trial Published preclinical study in Signal Transduction and Targeted Therapy shows piclidenoson restored protein reabsorption in Lowe syndrome models, cutting a urinary proteinuria marker by 48-80% over five months. A planned six-month Phase II study in 5 patients is under review by Italian health authorities. Form 6-K · SEC filing · Press release
Nov 9, 2026 ·
Clinical trial Can-Fite reported that a patient from its completed Phase II Namodenoson liver cancer study has reached ten years of overall survival and remains cancer-free. Separately, the pooled, blinded Phase III overall survival appeared longer than expected, so the planned interim analysis is being evaluated for earlier timing. Form 6-K · SEC filing · Press release
Nov 2, 2026 ·
Regulatory Can-Fite said the Eurasian Patent Office issued a notification of readiness to grant a patent covering Piclidenoson for diseases tied to OCRL deficiency, including Lowe syndrome and Dent disease 2. The patent is owned by research partner Fondazione Telethon, and the grant remains subject to completion of formalities. Form 6-K · SEC filing · Press release
Oct 26, 2026 ·
Clinical trial Can-Fite presented final Phase IIa pancreatic cancer data for namodenoson at ESMO 2026. The primary safety endpoint was met, with only five related or possibly related adverse events in three of 20 patients, all Grade 1–2. Form 6-K · SEC filing · Press release
Oct 9, 2026 ·
Financing Registers resale of up to 6,589,796 ordinary shares, represented by 3,294,898 ADSs, issuable on exercise of warrants under a warrant repricing. The company receives no proceeds from resales. ADSs closed at $2.10 on October 7, 2026. Form 424B3 · SEC filing
Sep 25, 2026 ·
Financing Can-Fite is registering for resale up to 6,589,796 ordinary shares, represented by 3,294,898 ADSs, issuable on exercise of warrants that were repriced. The company receives no proceeds from resale sales. ADSs closed at $2.16 on September 23, 2026. Form F-3 · SEC filing
Sep 8, 2026 ·
Listing Can-Fite reported that on January 2, 2026 it effected a 1-for-3,000 reverse split of its ordinary shares on TASE, and on January 5, 2026 changed the ADS ratio to one ADS representing two ordinary shares. Form 6-K · SEC filing · Press release
Sep 3, 2026 ·
Financing Can-Fite entered an inducement letter with a holder of existing warrants for 1,591,738 ADSs, reducing the exercise price from $5.00 to $2.50 per ADS in exchange for new warrants to buy 3,183,476 ADSs at $2.50. Form 6-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Aug 2027 · Phase 2 · Upcoming Trial · An Open-label, Phase 2 Pilot Study on the Efficacy and Safety of Piclidenoson in Patients With Lowe Syndrome Registry primary completion date, not a results date
Dec 2027 · Phase 3 · Upcoming Trial · A Phase 3 Study in Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and Efficacy Registry primary completion date, not a results date
Feb 2026 · Phase 3 · Recruiting · Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis Registry date passed, readout not confirmed
Jul 2026 · Phase 2 · Recruiting · Namodenoson Treatment of Advanced Pancreatic Cancer Registry date passed, readout not confirmed
Also used in these trials (approved or third-party drugs, not CANF's own candidates): Apremilast.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
CANF holds $7M in cash and short-term investments and burns about $2.4M/quarter from operations,
an estimated runway of 8.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:55 · Elevated
Cash runway 9 months +30
ATM program on file since May 2025 +15
Shelf registration (F-3, Aug 2026) +10
Recent financing filings on SEC EDGAR:
Aug 28, 2026 · Shelf registration, up to $100M · F-3
Share count 2,618,425 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full CANF picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CANF and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.